Helena Beer

The monoclonal antibody tislelizumab has been approved by the European Commission (EC) for use in patients with treatment-naive and relapsed non-small cell lung cancer (NSCLC), its manufacturer BeiGene has announced.

The cystic fibrosis (CF) medication ivacaftor (brand name Kalydeco) is safe and effective in infants aged four weeks and over, paving the way for earlier initiation of therapy for newborns diagnosed with the condition, a phase 3 open-label study has found.

A biomarker-based strategy is comparable to a magnetic resonance imaging (MRI)-enhanced approach for prostate cancer screening but results in more biopsies and increased detection of less aggressive cancers, a randomised trial has found.

Specific nasal cells found in children offer protection against Covid-19 infections and may explain why younger people typically experience milder Covid-19 symptoms than older adults, a new study has found.

An expanded guideline providing evidence-based recommendations for the management of adult and juvenile-onset Sjögren disease has been published by the British Society for Rheumatology (BSR).

Here at Hospital Healthcare Europe, we provide consultants and heads of hospital departments with inspirational examples of best practice, and that includes sharing insights into innovative projects being launched across the UK and Europe to support clinicians and improve patient care.

Speaking in an exclusive interview, NHS England's national digital primary care nurse lead Helen Crowther outlines the value of AI in healthcare and the importance of being curious about the digital future

Healthcare professionals prescribing montelukast as an oral add-on therapy for the treatment of asthma in patients aged six months or older should be alert to serious behaviour and neuropsychiatric reactions associated with the treatment, according to a new drug safety update.

Exhaled breath analysis shows promise as a non-invasive approach for the therapeutic monitoring of antibiotics, a proof-of-concept study has found.

The transthyretin stabiliser tafamidis (brand name Vyndaqel) has been recommended in final draft guidance by the National Institute for Health and Care Excellence (NICE) for the treatment of transthyretin amyloidosis cardiomyopathy (ATTR-CM).